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Introduction
Pancreatic cancer has shown little improvement in the 5-year survival 
rate since the 1970s (Rawla et. al. 2019)
CA19-9 is the most widely used biomarker for pancreatic cancer 
(Kleeff et. al. 2016)
Normalization of CA19-9, defined as levels < 40 U/mL, is associated 
with improved prognosis (Tzeng et. al. 2014)
We aimed to identify the trends of CA19-9 levels in patients with 
pancreatic cancer undergoing chemotherapy and develop a 
mathematical model that predicts outcomes to enhance treatment 
protocol.
Methods
• CA19-9 data was collected from 732 patients. 
• Patients were selected for modeling if they met the following 
criteria (Table 1):
• Baseline CA19-9 level above normalization (40 U/mL)
• Normal bilirubin prior to therapy(<2.0 mg/dL)
• No metastasis
• Uninterrupted FOLFIRINOX or Gemcitabine/Abraxene for 6 months
• 2+ CA19-9 measurements in addition to baseline 
• CA19-9 data were fit to a Type A (“A”lways decreasing) or Type 
B (“B”idirectional) exponential decay model (Fig. 1) 
• Y[t]=α*exp(β[t])
• Y(t): CA19-9 level at time t         • T(0): Chemotherapy start date
• Α and β: Model parameters describing the shape of the response curve 
• Model efficacy was compared to the “Ground Truth” (GT) 
presence or absence of CA19-9 normalization within 0-6 months
• ROC and Kaplan-Meier curves assessed model results
• Outcomes and patient trends were analyzed with Likelihood Ratio, 
Log Rank, and AUC tests
Conclusions
• The model performed well 
in predicting normalization 
for a small subset of 
patients but requires further 
refinement for enhanced 
prognostic capabilities and 
applications to more diverse 
patient profiles and CA19-9 
response patterns. 
• Ongoing work will examine 
additional parameters, test 
statistical models, and 
approach methods to 
account for continuous 
elevation of CA19-9.
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Fig 2. CA19-9 Normalization by Baseline Levels: Baseline CA19-9 
levels were evaluated with respect to eventual normalization and non-
normalization. Normalizers had a lower baseline CA19-9 (median 
148.55 U/mL [range 43.6-1562]) compared to non-normalizers 
(median 600.8 U/mL [range 53.2-8815], ANOVA, p=0.0016). 
Table 1. Patient Demographics: 86 patients met the criteria for inclusion. Patient counts are provided for normalizers and non-
normalizers; categorized by sex, median age, type of chemotherapy, and type of PDAC.
Fig 1. CA19-9 Prediction Model Design: Patients with CA19-9 levels decreasing during the initial period (t; 0-60) were fit 
to the Type A model (A). Patients with an increase in CA9-9 during the initial period followed by a decrease after T 
months were fit to the Type B model (B). Type B is a piece-wise defined curve where its first component has an 
increasing trend and the second has a decreasing trend of equal magnitudes with the turning point of f(t) as t=T.
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Fig 5. Kaplan-Meier Curves for GT and Model OS: Overall survival in 
days from the start of chemotherapy was plotted for normalizers and 
non-normalizers using GT and model responses. GT normalizers (A) had 
a median OS of 1037 days compared to 544 days for non-normalizers 
(Log rank, p= .0115). Model normalizers (B) had a median OS of 870 
days compared to 611 days for non-normalizers (Log-rank, p=0.2441)
Fig 4. Assessment of Model Accuracy: An ROC curve (A) for 
normalization of CA19-9 from the model’s prediction within 6 
months was generated to analyze model performance (AUC = 
.866). 73 of the 86 total patients had model results matching 
the GT presence or absence of normalization (B).
Results
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A. ROC Curve for Model Prediction of CA19-9 and 
Ground Truth for Normalization
B. Model Prediction for Normalization vs
Ground Truth
Fig 6. Visualization of Model Misclassification Shapes: 5 patients were misclassified as normalizers by the model: 2 demonstrated a “U-
shaped” change in CA19-9 (A) and 3 decreased without normalization (B). 8 patients were misclassified as non-normalizers by the 
model: 7 demonstrated a “bidirectional to normalization” change in CA19-9 (C) and 1 demonstrated an inconsistent rate of decline (D).
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Fig 3. CA19-9 Normalization by Disease Class: Proportions 
of patients that normalized in each disease class were 
assessed with Likelihood Ratios to determine if type of 
PDAC affects CA19-9 normalization. 11 of 26 patients with 
BR PDAC (A) normalized (p =0.4316). 13 of 46 patients 
with LA PDAC (B) normalized (p=.0027). 10 of 14 patients 
with Resectable PDAC (C) normalized (p=.1031).
A. Borderline Resectable PDAC
B. Locally Advanced PDAC
C. Resectable PDAC
• Normalizers displayed significantly lower baseline CA19-9 levels (p=.0016) compared to non 
normalizers (Fig. 2)
• Patients with LA PDAC are less likely to normalize (Likelihood Ratio, p=.0027) compared to 
patients with BR or Resectable PDAC (p > .05) (Fig. 3)
• Application of the model to predict CA19-9 normalization during 6 months of chemotherapy 
treatment accurately characterized 73 patients (AUC= .866) (Fig. 4) 
• Although both the GT and model responses demonstrated longer median OS for normalizers 
compared to non-normalizers, the difference was only statistically significant for the GT 
patients (Log rank, p = .0115) (Fig. 5)
• Analysis of misclassifiers showed specific response patterns associated with the inaccurate 
model prediction (Fig. 6)
